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Overexpression of 5-Hydroxytryptamine 2B Receptor Gene in Pulmonary Hypertension:
Still a Long Way to Understand its Transcriptional Regulation
To the Editor: I have read with great interest the recent report by Liu 1 concerning putative interactions between peroxisome proliferator-activated receptor (PPARγ) and 5-hydroxytryptamine 2B (5-HT 2B ) receptor in pulmonary arterial hypertension (PAH). Previous studies, including ours, demonstrated that 5-HT participates in PAH. A pathophysiological role of 5-HT 2B receptors was supported by the increased 5-HT 2B receptor expression in rodent lungs of hypoxia-or monocrotaline-induced PAH and corroborated by the genetic or pharmacological inactivation of 5-HT 2B receptors that prevented PAH development. 2 Other evidence already showed that the PPARγ agonist rosiglitazone was beneficial in preventing PAH, and PAH developed spontaneously in mice with smooth muscle cell-or endothelial cell-specific deletion of PPARγ. 3 Previous studies showed that the rat fundus contraction was mediated via the 5-HT 2B receptor subtype and reported potency (pEC50) for BW723C86 of 7.9. 4 Watts et al 5 identified the 5-HT 2A receptor in mediating the BW723C86-induced contraction of rat jugular vein with a pEC50 of 6.1. In Figures 3 and 4 , Liu claims that vasoconstriction in rats with pulmonary hypertension is mediated by 5-HT 2B receptors, although the pEC50 value for the 5-HT 2B agonist BW723C86 (<6 on Figure 3 ) is closer to that for 5-HT 2A receptors, questioning the implication of 5-HT 2B receptors. The only reported Ki value for (4-bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine hydrobromide (TCB-2) is at the 5-HT 2A receptor, but the affinity at 5-HT 2B or 5-HT 2C receptors is not defined.
Our recent article 6 showed that mice with restricted expression of 5-HT 2B receptors on bone marrow cells developed hypoxia-or monocrotaline-induced increase in pulmonary pressure, 5-HT 2B receptor expression, and vascular remodeling, whereas restricted elimination of 5-HT 2B receptors on bone marrow cells conferred a complete resistance. This was indicative that activation of 5-HT 2B receptors was required for the development of PAH 6 on bone marrow lineage progenitors, but not on lung-resident cells. The use of resident pulmonary artery smooth muscle cells on Figures 5 and 6 of Liu's article are therefore not relevant to the pathological cells that express 5-HT 2B receptors in PAH lungs. Furthermore, the authors missed the presence of a 5′-noncoding exon in mouse, rat, and human HTR 2B gene. In addition, using the transcription element search system (http://www.cbil.upenn.edu/cgibin/tess/tess), we found that the transcription factor activator protein-1 (AP-1)-binding sites identified in the 5′-flanking region of rat HTR 2B by Liu are not evolutionarily conserved. As shown on Figure 1 , a weak AP-1-binding consensus is found 5′ of the first exon in mice and rat, but not human, promoter. For the 3′ (intronic) site, a weak double AP-1 site in rat is partially conserved in human, but not in mouse, sequence. Finally, chronic exposure to 5-HT 2B receptor antagonists prevented PAH and plasma 5-HT increase, but not 5-HT 2B receptor overexpression, 6 excluding, at least in vivo, a feed-forward regulatory mechanism, as suggested by Liu.
To sum up, the relation between PPARγ and 5-HT 2B receptors needs further research to determine if the Htr 2B is a direct target of PPARγ action on the vascular contraction and remodeling in PAH. Full set of research is also needed to demonstrate a putative role for 5-HT in transcriptional regulation of Htr 2B promoter.
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